Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia : mathematical modelling study.

Tools

Stanciole, Anderson E. and Ortegón, Mónica and Chisholm, Dan and Lauer, Jeremy A. (2012) Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia : mathematical modelling study. BMJ (Clinical research ed.), 344. pp. 1-12. e608. ISSN 1756-1833 (https://doi.org/10.1136/bmj.e608)

[thumbnail of Stanciole-etal-BMJ2012-Cost-effectiveness-strategies-combat-chronic-obstructive-pulmonary-disease-asthma-sub-Saharan-Africa-South-East-Asia]
Preview
 Text. Filename: Stanciole_etal_BMJ2012_Cost_effectiveness_strategies_combat_chronic_obstructive_pulmonary_disease_asthma_sub_Saharan_Africa_South_East_Asia.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial 4.0 logo
Download (501kB)| Preview

Abstract

To determine the population level costs, effects, and cost effectiveness of selected, individual based interventions to combat chronic obstructive pulmonary disease (COPD) and asthma in the context of low and middle income countries. Sectoral cost effectiveness analysis using a lifetime population model. Two World Health Organization sub-regions of the world: countries in sub-Saharan Africa with very high adult and high child mortality (AfrE); and countries in South East Asia with high adult and high child mortality (SearD). Disease rates and profiles were taken from the WHO Global Burden of Disease study; estimates of intervention effects and resource needs were drawn from clinical trials, observational studies, and treatment guidelines. Unit costs were taken from a WHO price database. Cost per disability adjusted life year (DALY) averted, expressed in international dollars ($Int) for the year 2005. In both regions low dose inhaled corticosteroids for mild persistent asthma was considered the most cost effective intervention, with average cost per DALY averted about $Int2500. The next best value strategies were influenza vaccine for COPD in Sear-D (incremental cost $Int4950 per DALY averted) and low dose inhaled corticosteroids plus long acting β agonists for moderate persistent asthma in Afr-E (incremental cost $Int9112 per DALY averted). COPD is irreversible and progressive, and current treatment options produce relatively little gains relative to the cost. The treatment options available for asthma, however, generally decrease chronic respiratory disease burden at a relatively low cost.

ORCID iDs

Stanciole, Anderson E., Ortegón, Mónica, Chisholm, Dan and Lauer, Jeremy A. ORCID logoORCID: https://orcid.org/0000-0003-0652-0691;
CORE (COnnecting REpositories)